Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
766.460.07%
QQQ
719.560.17%
BTC/USD
79643.921.5179%
DIA
527.690.06%
GLD
403.861.04%
TLT
82.140.07%

Syndax Pharmaceuticals Inc

SNDXNASDAQ
Trade with Public
Trade with Public
$19.94
-0.62-3.02%
At close: Sep 4, 5:00 PM EST
$19.94
-0.62-3.02%
Pre-Market: 4:09 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Syndax Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Syndax Pharmaceuticals (SNDX).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

13Buy
1Hold
Consensus RatingBuy# Analysts14Avg. Consensus PT$38Upside to Avg. PT+88.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026UBSDavid DaiPT CutBuy$37→$33
Aug 11, 2026JP MorganAnupam RamaPT CutOverweight$44→$40
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33

UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $40 to $38.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved